1710 related articles for article (PubMed ID: 25978875)
1. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents.
Matsui K; Tsume Y; Amidon GE; Amidon GL
Mol Pharm; 2015 Jul; 12(7):2418-28. PubMed ID: 25985298
[TBL] [Abstract][Full Text] [Related]
3. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
[TBL] [Abstract][Full Text] [Related]
4. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a three compartment in vitro gastrointestinal simulator dissolution apparatus to predict in vivo dissolution.
Takeuchi S; Tsume Y; Amidon GE; Amidon GL
J Pharm Sci; 2014 Nov; 103(11):3416-3422. PubMed ID: 25251982
[TBL] [Abstract][Full Text] [Related]
6. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
[TBL] [Abstract][Full Text] [Related]
7. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
[TBL] [Abstract][Full Text] [Related]
8. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
9. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
10. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
11. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pH dependent absorption using in vitro, in silico, and in vivo rat models: Early liability assessment during lead optimization.
Saxena A; Shah D; Padmanabhan S; Gautam SS; Chowan GS; Mandlekar S; Desikan S
Eur J Pharm Sci; 2015 Aug; 76():173-80. PubMed ID: 25960252
[TBL] [Abstract][Full Text] [Related]
13. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
14. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
16. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole.
Matsui K; Tsume Y; Takeuchi S; Searls A; Amidon GL
Mol Pharm; 2017 Apr; 14(4):1181-1189. PubMed ID: 28231003
[TBL] [Abstract][Full Text] [Related]
18. An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products.
Gonzalez-Alvarez I; Bermejo M; Tsume Y; Ruiz-Picazo A; Gonzalez-Alvarez M; Hens B; Garcia-Arieta A; Amidon GE; Amidon GL
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917118
[TBL] [Abstract][Full Text] [Related]
19. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.
Varum FJ; Merchant HA; Goyanes A; Assi P; Zboranová V; Basit AW
Int J Pharm; 2014 Jul; 468(1-2):172-7. PubMed ID: 24727141
[TBL] [Abstract][Full Text] [Related]
20. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]